Latest News

Results from an ITN study published today in the Journal of the American Medical Association demonstrated successful weaning of anti-rejection drugs in pediatric liver transplant recipients (results here).  Results from this multicenter pilot study, led by Sandy Feng, MD, PhD (University of California, San Francisco), suggest that certain children undergoing liver transplantation from a parental living donor may be able to maintain their organ without the burdens of lifetime immunosuppression.This study enrolled 20 highly-selected pediatri

In an ITN supported study recently published in American Journal of Transplantation a new potential indicator of clinical outcome in renal transplant recipients has been identified (results here). The signature was identified from samples collected under the ITN study, “ITN registry of tolerant kidney transplant recipients” led by Kenneth Newell, MD (results reported here).

In April 2011 the FDA approved Rituximab (anti-CD20; Genentech) for use in granulomatosis and microscopic polyangiitis based on results from the ITN RAVE study. Before the Rituximab label extension, the standard of care for this disease was cyclophosphamide, a potent immunosuppressant that although effective is very toxic when used long-term.

The ITN's T1DAL research trial for recently diagnosed type 1 diabetes has recently received the approval of its Data Safety Monitoring Board (DSMB) to begin accepting patients in the younger cohort, ages 12-15 years, into the study. The decision was made after a review of safety data from the initial group of 10 adult-age subjects enrolled into the study.